Bortezomib-associated tumor lysis syndrome in multiple myeloma

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2380-2382

  Furtado, Michelle ^a   Rule, Simon ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CALCIUM; CREATININE; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; LACTATE DEHYDROGENASE; MELPHALAN; PHOSPHATE; POTASSIUM; PREDNISOLONE; RASBURICASE; SODIUM; THALIDOMIDE; UREA; URIC ACID;

AGED; ARTICLE; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CASE REPORT; CELL INFILTRATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HUMERUS FRACTURE; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PANCYTOPENIA; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

AGED; BORONIC ACIDS; FEMALE; HUMANS; MULTIPLE MYELOMA; PYRAZINES; TUMOR LYSIS SYNDROME;

EID: 57449101621     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802484099     Document Type: Article

References (15)

1. Hochberg, J. and Cairo, M. S. (2008) Tumor lysis syndrome current perspective. Haematologica, 93, pp. 9-12.
2. Kalemkerian, G. P., Darwish, B. and Varterasian, M. L. (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med, 103, pp. 363-367.
3. Baeksgaard, L. and Sorenson, J. B. (2003) Acute tumor lysis syndrome in solid tumors: A case report and review of the literature. Cancer Chemother Pharmacol, 51, pp. 187-192.
4. San Miguel, J F, Almeida, J. and Orfao, A. (2002) Laboratory investigations'. Myeloma, pp. 243-268. Martin Dunitz, London
5. Terpos, E., Politou, M. and Rahemtulla, A. (2004) Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol, 130, pp. 623-625.
6. Sezer, O., Vesole, D., Singhal, S., Richardson, P., Stadtmauer, E. Jacob, C. et al. (2006) Bortezomib-induced tumour lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma, 7, pp. 233-235.
7. Fassas, A. B., Desikan, K. R., Siegal, D., Golper, T. A., Munshi, N. C. Barlogi, B. et al. (1999) Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol, 105, pp. 938-941.
8. Richardson, P. G., Barlogi, B., Berenson, J., Singhal, S., Jagannath, S. Irwin, D. et al. (2003) A phase II study of bortezomib in refractory and relapsed myeloma. N Engl J Med, 348, pp. 2609-2617.
9. Karin, M., Cao, Y., Florian, R., Greten, F. R. and Zhi-Wei, L. (2002) NF-kappa in cancer: From innocent bystander to major culprit. Nat Rev Cancer, 4, pp. 301-310.
10. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D. Richardson, P. et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, pp. 1530-1534.
11. Millenium Pharmaceuticals (2006) Velcade for Injection [summary of product characteristics], Millenium Pharmaceuticals, Cambridge, MA
12. Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E. Facon, T. et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352, pp. 2487-2498.
13. Kenealy, M. K., Prince, H. M. and Honemann, D. (2006) Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy, 26, pp. 1205-1206.
14. Jaskiewicz, A. D., Herrington, J. D. and Wong, L. (2005) Tumor lysis syndrome after bortezomib therapy for plasma cell leukaemia. Pharmacotherapy, 25, pp. 1820-1825.
15. Chim, C. S. (2008) Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumour lysis syndrome. Cancer Chemother Pharmacol, 62, pp. 181-182.